Open AccessA case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy
Author(s) -
Н. С. Руднева,
Э. В. Натарова,
V. Sorotskaya,
T. G. Sadunashvili
Publication year - 2021
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2021-6-106-110
Subject(s) - vitiligo , psoriasis , medicine , depigmentation , dermatology , adalimumab , psoriatic arthritis , biosimilar , disease
The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), vitiligo and autoimmune thyroiditis made it possible to control the activity of psoriasis and PsA, and also contributed to the regression of depigmentation foci. The use of biologic disease-modifying antirheumatic drug therapy in this group of patients in order to achieve repigmentation may be promising.